Disparities in 10-year local recurrence following breast-conserving surgery were seen among women with ductal carcinoma in situ (DCIS) treated over a nearly 4-decade span at Memorial Sloan Kettering ...
A Decision Score provides prognostic discrimination for 10-year locoregional recurrence, with rising score associated with ...
Adjuvant tamoxifen may reduce recurrence risk for patients with ‘good-risk’ DCIS who forgo radiation
SAN ANTONIO – For patients with “good-risk” ductal carcinoma in situ (DCIS) who underwent breast- conserving surgery and did not receive radiotherapy, tamoxifen significantly decreased the risk of ...
The incidence of invasive breast cancer after conservative treatment for ductal carcinoma in situ (DCIS) decreased by more than 50% over the past 30 years, data from a Dutch cancer registry showed.
SAN ANTONIO – Among patients with hormone receptor (HR)-positive, HER2-negative, low-risk ductal carcinoma in situ (DCIS), those who underwent active monitoring had similar two-year invasive ...
Impact of HER2 low status on pathologic response after neoadjuvant chemotherapy in TNBC: A large scale retrospective cohort study. Impact of postmastectomy radiotherapy on health-related quality of ...
October 27, 2009 — Women with low- to intermediate-grade ductal carcinoma in situ (DCIS) with margins 3 mm or wider had an "acceptably low rate" of ipsilateral breast events 5 years after excision ...
SAN ANTONIO ― Oncologists can now offer postmenopausal women with ductal carcinoma in situ (DCIS) two options for prevention of breast cancer recurrence: anastrozole (Arimidex, AstraZeneca ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results